Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

August 11, 2022

NASDAQ US Health Care Life Sciences Tools and Services earnings 59 min

Earnings Call Speaker Segments

Francis deSouza

executive
#1

Good afternoon, everyone. Illumina's revenue for the second quarter came in at $1.16 billion, which represents a 3% increase compared to the same period last year, and 5% when measured on a constant currency basis. Sequencing activity was strong across the markets we serve during the second quarter — runs on our connected high and mid-throughput platforms rose over 15% versus a year ago, and clinical activity grew at an even quicker pace. Even so, our second-quarter results took a hit from macroeconomic headwinds we anticipate will continue working through the next couple of quarters. To be specific, certain customers ran into supply chain constraints, which pushed back their lab expansion plans, while others took a more cautious approach to inventory and capital management; we additionally faced unfavorable foreign exchange movements and the COVID-related shutdowns we had expected in China. The strong levels of sequencing activity, the fundamental expansion of the markets we target, and what we are hearing from customers around the world all point to these pressures being short-lived. We also achieved excellent progress against our innovation roadmap during the quarter, and we are positioned to bring the next generation of breakthrough technologies to market soon, which will power genomics' next era. Now let me move to how each of our platforms performed. On the high-throughput side, NovaSeq shipments rose 23% from a year earlier in the second quarter, marking our strongest Q2 on record. As in previous quarters, clinical customers — chiefly those in oncology testing — accounted for half of the NovaSeq units we shipped; on the mid-throughput side, orders for NextSeq 1000/2000 climbed 20% versus the prior-year period. Even though supply delays caused some shipments to slide out of the second quarter into the third, NextSeq 1000/2000 shipments still edged up slightly year-over-year in Q2. Low-throughput shipments stayed roughly level compared with a year ago, despite going up against last year's volume, which was driven by COVID surveillance. Moving to our markets, we keep building momentum in clinical, where second-quarter sequencing consumable shipments rose 11% from a year earlier, with every one of our clinical markets adding to that gain. As I noted before, our oncology markets have continued to expand. Oncology consumables were up nearly 20% year-over-year in Q2. One thing worth highlighting is our market-leading TruSight Oncology assay. TSO shipments climbed 45% compared with a year ago, and we have now supplied distributed comprehensive genomic profiling tests to every major market worldwide. We have collaborated closely with large evidence programs to support clinical utility and open up market access, and over 10 pharma partners are working with us to develop CDX claims. Most recently, we broadened our portfolio by co-developing a new TSO 500 HRD test alongside Merck that builds on Illumina's collaboration with Myriad Genetics. With Bayer, we also co-developed a pan-cancer companion diagnostic for TSO Comprehensive EU. Still on oncology, June brings the one-year anniversary of Grail's launch of Galleri. Over that period, Galleri achieved the fastest first-year revenue ramp ever recorded for a cancer screening test. Grail keeps making headway on generating clinical evidence and on commercial adoption of its multi-cancer early detection test, Galleri. The roster of U.S. health systems working with Grail to make Galleri available keeps expanding, with Mercy — among the 25 largest U.S. health systems — and Ochsner Health, the largest health system in the Gulf South, joining most recently. Grail also recently entered a partnership with AstraZeneca to develop companion diagnostic tests that will pinpoint patients with high-risk, early-stage disease. AstraZeneca is going to leverage Grail's technology for finding early-stage cancer patients to enroll in its clinical trials, so that cancer treatments can be offered in situations where the chance to change outcomes is bigger. On a wider scale, the trials for Galleri that are running right now keep moving forward. In the UK, the NHS-Galleri trial — the biggest study for early detection across multiple cancers — has brought in 140,000 volunteers in only a bit more than 10 months, which is an unheard-of pace, particularly given how large this trial is. If the trial wraps up successfully, the NHS intends to make Galleri available to another 1 million individuals beginning in 2024; this partnership backs the NHS long-term plan for changing cancer care, aiming for three out of four cancers to be caught at an early stage by 2028. On top of that, Grail has wrapped up a final analysis of its Pathfinder study, and the data will be shared at the European Society for Medical Oncology Congress, from September 9th to 13th. Grail has achieved significant headway in creating a partner network that will back the continued uptake of Galleri, though commercial advancement is happening more gradually while health systems scale up. Because of this, Grail has lowered its revenue guidance for the entire year 2022 to a range of $50 million-$70 million. Moving on to infectious disease and microbiology, the genomic surveillance infrastructure that was established on Illumina instruments throughout the pandemic in over 100 countries is now being applied to other illnesses such as monkeypox; this network is allowing faster genetic evaluation of this emerging disease as support grows for a strong worldwide pathogen infrastructure. We are growing our surveillance offerings in response; during June, we gave certain customers access to our new viral surveillance panel built on the workflows used for COVID-19. This panel delivers targeted sequencing for the 66 most essential viruses that pose global public health threats, such as monkeypox and polio, and it will be offered commercially before this year ends. Our research and applied markets stayed roughly level compared with a year ago, as gains in the Americas and APJ were canceled out by decreases in EMEA and China. During the quarter, we shared news of our partnership with Precision Health Research, Singapore, also known as PRECISE, to sequence whole genomes from 100,000 participants in Singapore. Jointly, we will build the most thorough population study in Southeast Asia and obtain deep understanding of Asian genomic diversity along with important genetic, social, environmental, and other elements tied to disease. Before I bring you up to date on additional developments in our innovation roadmap, I'll hand the call over to Joydeep.

Joydeep Goswami

executive
#2

Thank you, Francis. Just to note, our second-quarter financials incorporate Grail's consolidated results. I'll begin with a look at our consolidated numbers, then move on to segment performance for Core Illumina and Grail, and finish with some further comments regarding our updated view for 2022. My remarks will focus on non-GAAP results, which factor in stock-based compensation. Please take a look at the GAAP reconciliation for these non-GAAP measures, available in today's release and in the supplementary data posted on our website; during Q2, consolidated revenue reached $1.16 billion, a rise of 3% compared with the prior year, or 5% when measured in constant currency, net of hedging effects. Those results felt the weight of the macroeconomic pressures Francis mentioned. As you're aware, we had expected challenges stemming from China's shutdowns, unfavorable FX movement, and a decline in COVID surveillance. Every one of those came in a bit softer than anticipated, and together they accounted for one quarter of the gap between what we expected and what we actually delivered. The rest of that gap came from delays in lab expansion that a handful of our major customers ran into because of global supply chain constraints, along with customer inventory and capital management. Even so, sequencing activity overall across our connected instruments was robust during Q2, with runs on our high and mid-throughput platforms rising over 15% versus the prior year. We see this as a helpful benchmark reflecting the broader activity pattern within our installed base, and it tends to move in the same direction as revenue over time; during Q2, GAAP net loss came to $535 million, equal to a loss of $3.40 per diluted share, and that figure included $609 million of legal contingencies booked in Q2 tied to a possible fine the European Commission could levy over our Grail acquisition plus the settlement of our BGI litigation. Non-GAAP earnings totaled $91 million, or $0.57 per diluted share, which includes dilution from Grail's non-GAAP operating loss of $152 million during the quarter. Our non-GAAP tax rate stood at 25.8%, up 790 basis points from a year earlier and 800 basis points versus Q1 2022, largely because of the greater effect of R&D expense capitalization rules put in place under the Tax Cuts and Jobs Act of 2017. Our non-GAAP weighted average diluted share count for the quarter was roughly 159 million. Turning to segment results, I'll first cover Core Illumina's financial performance. Core Illumina revenue came in at $1.16 billion, up 3% from a year ago, or 4% in constant currency, net of hedging effects. Core Illumina sequencing consumables rose 6% year-over-year to $744 million, powered by growth of nearly 20% in oncology testing. That consumables growth more than made up for headwinds tied to China lockdowns, the wrap-up of the UK Biobank program in quarter three of 2021, lower COVID surveillance, and unfavorable FX. Sequencing instruments revenue at Core Illumina increased 1% year-over-year to $119 million, helped by 23% growth in NovaSeq shipments, though that was partly offset by a 14% drop in mid-throughput shipments versus the prior year. The decline in mid-throughput shipments largely stemmed from COVID surveillance and lockdown-related challenges in China, since growth in NextSeq 1000/2000 was outweighed by a drop in NextSeq 550. Our NextSeq 1000/2000 instruments kept expanding compared with the prior year, and that expansion would have been even better without temporary supply limitations that pushed shipments into Q3. Orders for NextSeq 1000/2000 rose 20% versus the prior year, reflecting ongoing robust uptake of our newest platform. In Q2, COVID surveillance accounted for roughly $25 million of sequencing consumables revenue plus $2 million of incremental instruments revenue, which marked a 55% decline versus the prior year; that drop came from lower-than-anticipated testing samples and the anticipated reduction in instrument shipments, since COVID surveillance capacity was mostly built out in 2021. Core Illumina sequencing service and other revenue reached $125 million, a 2% decline versus the prior year, caused by $20 million of one-time revenue recorded in 2021 from NIPT royalties tied to a patent litigation settlement. This was partly offset by more instrument service contracts and contributions from oncology co-development partnerships. Turning to regional results for Core Illumina. Americas region revenue totaled $633 million, rising 7% versus the prior year, mainly on NovaSeq strength amid sustained demand from oncology testing customers, which fueled instrument placements and consumables growth. Even so, growth in the region fell short of expectations, largely because of customer lab expansion delays along with the inventory and capital management matters we discussed during the call. EMEA revenue came to $308 million, a 4% decline versus the prior year, yet a 1% gain on a constant currency basis after accounting for hedge effects. Sequencing growth from clinical and large scale research projects was more than outweighed by the 2021 UK Biobank program and a reduction in COVID surveillance revenue. Taken together, these substantial headwinds and effects reduced year-over-year revenue growth by 20 percentage points. Greater China revenue reached $118 million, an 11% decline versus the prior year and a 10% decline on a constant currency basis. That was somewhat worse than the roughly $35 million headwind to guidance we gave last quarter. As anticipated, the region remained affected by extended COVID-19 restrictions and shutdowns that started in March this year. Lastly, APJ revenue of $97 million increased 14% versus the prior year, or 20% on a constant currency basis, after accounting for hedge effects. Growth there was mainly driven by higher NovaSeq shipments, which doubled versus the prior year, on large-scale research project demand along with strength in NIPT and oncology testing. Now to the remaining Core Illumina P&L items. Core Illumina non-GAAP gross margin was 69.8%, down 200 basis points versus the prior year, chiefly because of reduced fixed cost leverage on lower manufacturing volumes, the margin effect of one-time revenue from a 2021 patent litigation settlement, and higher freight costs tied to broader global supply chain pressures. These factors were partly offset by a more favorable product mix and several productivity initiatives we keep pursuing. On the Core Illumina side, non-GAAP operating expenses came to $519 million, which is $48 million higher than the same period a year ago. The main drivers there are growth in headcount along with the R&D investments we're funding to keep pushing our innovation roadmap forward. Even with that year-over-year climb, Core Illumina non-GAAP opex landed below what we had initially budgeted, and that's because performance-based compensation came in lower given the reduced revenue outlook, plus the cost containment work we did around certain hires and discretionary items like travel. Now shifting over to how Grail performed financially. Grail's revenue for the quarter was $12 million, mostly from Galleri test fees. Grail non-GAAP operating expenses for the quarter added up to $156 million, largely tied to headcount and clinical trial costs. Those came in under expectations, since Grail reined in its project spending in response to a softer quarterly outlook. Let's turn to consolidated cash flow and balance sheet items. Operating cash flow was $125 million. DSO came in at 50 days, versus 46 days in the prior quarter, driven by revenue linearity. Capital expenditures for Q2 2022 were $71 million, with free cash flow of $54 million. No common stock was bought back during the quarter; we finished it holding roughly $1.3 billion in cash equivalents and short-term investments. Let's move on now to the 2022 guidance.

Joydeep Goswami

executive
#3

We've revised our outlook for the entire year to account for the macroeconomic situation observed up through the beginning of August, and we anticipate those conditions will continue through the rest of 2022. For the full year, our expectation now is consolidated revenue growth between 4% and 5%. Within that, Core Illumina revenue growth is projected at 3.5% to 4.5%, while Grail revenue is expected to land somewhere between $50 million and $70 million. If we take the midpoint of that revenue guidance range, Core Illumina sequencing revenue should rise by about 4.5% across the full year. That number accounts for roughly $25 million of intercompany sales made to Grail, which are removed when we consolidate. When it comes to Core Illumina sequencing revenue, our instrument growth expectation is now 1.5%, while consumables are projected at 5%, which accounts for NovaSeq pull-through of $1.1-$1.2 million for each system in 2022. Regarding NextSeq 1000/2000, our pull-through expectation remains $130,000-$180,000 for each system, and for NextSeq 550, it stays at $100,000-$150,000 per system. On MiSeq, we still anticipate pull-through of $35,000-$45,000 for each system, and on MiniSeq, our expectation continues to be $20,000-$25,000 per system; COVID surveillance revenue is now projected at $110 million-$130 million. Though we had expected COVID surveillance to fall in 2022, the slowdown occurred more rapidly than our earlier projection. While dealing with the macro pressures we already brought up, there are several approaches we're putting into action. These include putting key innovation spending and important hires first, while holding off on investments that could wait until a later point. Every essential investment in our innovation roadmap remains in place, such as NovaSeq DX, Chemistry X, Infinity long-read technology, and the TSO portfolio. Our updated outlook calls for consolidated non-GAAP operating margin between 11.5% and 12%, along with Core Illumina non-GAAP operating margin between 24.5% and 25%. For the consolidated non-GAAP tax rate, we anticipate roughly 14%, and this still bakes in the assumption that the R&D expense capitalization rules from the Tax Cuts and Jobs Act of 2017 will either be repealed or pushed back in Q4. Our updated projection for non-GAAP earnings per diluted share is now $2.75 to $2.90. That figure accounts for roughly $610 million in dilution tied to Grail's non-GAAP operating loss, matching what we previously guided. Turning to the final item, we still anticipate diluted shares outstanding near 159 million for 2022. For Q3 of 2022, consolidated revenue should come in flat to 1% higher compared with Q3 of 2021. On profitability, we're looking at a consolidated non-GAAP operating margin around 5%, while Core Illumina's non-GAAP operating margin should land near 20%. As for taxes, the consolidated non-GAAP rate should be about 22%, and that continues to capture the drag from R&D capitalization requirements that we believe will be repealed or pushed out during Q4 of this year. To wrap up, our projection for diluted shares outstanding matches what we laid out in our full-year 2022 guidance — roughly 159 million shares. At this point, I'll turn things back to Francis so he can share his closing thoughts.

Francis deSouza

executive
#4

Appreciate it, Joydeep. Now, if we look at where we're headed with innovation, there's a lot of room to rethink what genomics can do and how powerful it can become. When it comes to NovaSeq DX — the very first clinical sequencer built for high throughput — our development and registration work is moving along exactly as we laid out, and we remain on schedule to launch in Q4. Feedback keeps coming in from the first customers using our Infinity long-read technology, and a lot of them tell us it could take the place of long reads already on the market across a wide set of uses, human rare diseases among them. Infinity should reach early access customers before this year is over, right on plan. On the multi-omics side, things are moving forward with SomaLogic as we work together to push NGS further into proteomics, and we still expect to bring out our assay with ultra-high throughput and ultra-high plexity during 2024. Let's shift to Chemistry X, the breakthrough next-generation SBS chemistry we've developed. The past quarter brought tremendous strides. Our new manufacturing approach, which relies on 300 millimeter wafers, is now being used to produce flow cells. We put Chemistry X through testing on those new flow cells, and it came back better than we had hoped on quality, cost, and speed. We can't wait to show off these advances and demonstrate how they work in practice at the Illumina Genomics Forum. It will be our pleasure to have you join us for Investor Day on October 3rd, when we'll go through these technologies along with our plans for growth over the long term. Should you not have signed up yet, please make sure you do that before long. At this point I'd like to ask the operator to open up the line so we can take your questions.

Derik De Bruin

analyst
#5

Hello. Good afternoon. Francis, the remarks about lab expansion leave me somewhat puzzled. Nothing from our channel checks or our conversations at ASCO in June pointed to this taking place. Is the real problem that your clinical customers aren't expanding? What makes you certain it wasn't caused by those customers possibly evaluating rival products? And precisely how much consumable inventory remains in the channel? Thank you.

Francis deSouza

executive
#6

Hello, Derik. Regarding lab expansion, what took place in Q2 was that a handful of our customers who intended to open new labs or enlarge existing ones ran into delays of their own making, tied to supply chain problems on their end. The equipment they anticipated receiving for those enlarged labs failed to arrive when they thought it would; we observed a handful of lab expansion plans pushed back, a few moving into Q2, some into Q3, and one sliding into Q4 of next year. Naturally, since we maintain such a tight relationship with our customers, we are aware of the details behind those lab expansions. Let me be clear: those lab expansions have been delayed, yet they continue to move forward. That is what is behind the figure we discussed for Q2 and for the remainder of the year. On the inventory side, what is unfolding is that certain customers of ours who want to keep a tighter grip on their capital are keeping fewer goods stocked at their own locations. They feel quite confident about how resilient our supply chain is, so they intend to reduce the inventory amounts they keep on their own premises. From where we sit, we anticipate this will continue; it began in Q2 and will carry on somewhat through three and four too. Ultimately, though, their demand and their activity levels will line up with what the data from monitoring their instruments tells us. There, activity—and consequently demand—remains extremely strong. As we mentioned in Q2, the activity levels we track on the high and mid-throughput instruments showed a growth rate for runs above 15%. So as we get past these temporary effects, we firmly anticipate that demand, and thus orders, will align much more closely with the activity levels we observe.

Dan Brennan

analyst
#7

Hi there, and thanks for letting me ask. I suppose this is partly a follow-up on what Derek raised, plus one connected to it. Francis, could you talk about how big that second-half drop actually is? Under the revised outlook you've given, Core Illumina growth now points to something roughly flat across the latter six months, whereas at the start your guidance pointed toward the high teens. That's quite a swing, and it comes down to a handful of customers. Could you add a bit more detail there — is there a reasonable cushion of prudence built into these numbers? And how should we square such a large reduction with only a few customers pulling back? Then, tying into what Derik mentioned, are you noticing any hold-ups — perhaps customers waiting on Chemistry X to arrive, or effects from the competitive chatter in the market? Honestly, a pause while people assess new offerings would strike me as easier to accept as the reason for this cut. Thank you.

Francis deSouza

executive
#8

Yes, I appreciate that, Dan. Let me begin with the back half, and after that I'll hand things to Joydeep so he can put some sizing around the various elements we described. Based on what we observe and what our customers tell us, the difficulties they're working through involve holdups in expanding their labs — as I mentioned, tied to managing their own supply chains as they grow those labs — along with stricter control over inventory; those truly accounted for several of the main reasons behind the shift, together with a modest amount of foreign exchange effects and similar items. According to them, Chemistry X isn't actually behind this, nor are competitive matters; as a matter of fact, they're eager about Chemistry X and want to find out more when the Illumina Genomics Forum takes place. The elements we discussed are genuinely what's behind the change. Joydeep, perhaps I'll pass it to you so you can provide additional detail on how large each of those is.

Joydeep Goswami

executive
#9

Alright, and thank you, Francis. So Dan, to start with your question about whether the guidance for the back half of the year is conservative — what we actually think, looking at the patterns we've been observing, is that this is a balanced outlook. Upsides and downsides always exist. The elements we identified during Q2, in our view, will carry forward across the remainder of this year. If we try to put a size on them, roughly 25% of the reduction versus our guidance is genuinely attributable to things like foreign exchange, the quicker-than-anticipated escalation on the COVID front, and a portion of the softness we've encountered in China, which is tied more to GDP-driven consequences for the research portion of our operations there. The remaining 75% or thereabouts connects to what Francis mentioned — specifically the delays in lab expansion stemming from wider supply chain pressures hitting the build-out of labs at our customers, and then their efforts to bring new assays and instruments online. Then there are the effects of macroeconomic headwinds on our customers, which are producing a short-term drawdown in inventory levels along with certain capital push-outs.

Dan Arias

analyst
#10

Good afternoon, everyone. Thank you. Francis, I want to return to the consumables topic for a moment. You've made the point repeatedly that the sequencing outlook looks strong, since that work basically must be performed to enable patient assessment. So then, what exactly caused purchasing to stall so suddenly? Is the bigger factor increased activity on the commercial development side, things such as liquid biopsy efforts, or are you truly observing reduced spending at patient-facing institutions, clinical oncology institutions, and so forth? And as a second question, why wasn't there a pre-announcement when Sam departed? With only 3 weeks remaining in the quarter, it appears a miss was clearly developing by then. Thanks.

Francis deSouza

executive
#11

I'll handle both sides of what you asked, Dan. First, let's get into the consumables and demand issue. Well, you've got that right. Since we cater to clinical customers, a large portion of the people we serve keep experiencing strong demand. They're going after, say, cancer patients whose tissue has to be biopsied and afterward sequenced, or who need ctDNA tests. That shows up in the activity levels we recorded in Q2 — even when customers wanted to keep their inventories under tighter control, they kept their machines running at full tilt, correct? We noted that, on the whole, if you look at how much the mid and high throughput instruments we track are being run, among the customer base we track, run counts were up 15% year-over-year. Within the clinical markets, it was in fact greater, for precisely the reasons you brought up — our clinical market customers, particularly in fields such as oncology, therapy selection testing, which is the biggest segment we serve, keep seeing strong demand, and their activity levels showed it. Now, as we mentioned, customers want to handle their cash in a more cautious way, so they cut down how much inventory they keep at their sites. They're able to do that as a single rebalancing downward, yet in the end their ordering levels are going to line up with the activity levels on their instruments. That's the reason we anticipate this effect will unfold a bit in Q2 and a bit over the quarters ahead. Order rates are going to match, in our view, the real activity we observe on their machines. Let me say something about the Sam matter. When Sam departed, as we stated, he departed for personal reasons and had to be on the East Coast. That's what we said at the time he left, clearly. From where we sit, our quarters are usually weighted toward the back end. The effects I described grew clearer toward the quarter's close. So there was no color commentary when Sam departed.

David Westenberg

analyst
#12

Hello, and thanks for fielding my question. Yeah, apologies, I want to return to how the guidance breaks down here. If you reverse-engineer that guidance, it appears to be $400 million, and FX deteriorated — I'm not sure whether you'd like to put a figure on that. COVID surveillance, what does that amount come to, I know Grail accounted for $20 million, plus the lab expansion. Is there anything beyond those items, other factors, that perhaps you could identify? I want to revisit the instrument, or rather the backlog here. You folks sounded quite confident about the backlog as you closed out the quarter. It appears those orders perhaps didn't materialize the way you thought, or come through as anticipated — what's happening there? Thank you.

Francis deSouza

executive
#13

Yes. David, I appreciate the question. Allow me to restate what I noted before, correct? Two general categories — roughly 25% of the shortfall centered on items that encompassed FX, the quicker than anticipated drop-off in COVID surveillance, China, and a portion of the macroeconomic impacts we're observing during the back half of the year, which aren't tied directly to the lockdown, but rather the GDP growth that's slower than anticipated there, correct? Then the remaining category, 75%, essentially consisted of two elements — the lab expansion postponements, which, once again, we anticipate returning in 2023. These are remarks we've heard straight from our customers. The other element concerned inventory buildup, or restocking, happening more slowly than anticipated, along with certain capital deferrals from a wider group of customers. Once again, as Francis stated, we anticipate these being temporary. Regarding the backlog, I'd say the backlog we carry out of Q2 is a solid $1.1 billion. That matches what we've observed across the prior six quarters. Once again, backlog shifts somewhat quarter to quarter, as one would anticipate, yet this is very much consistent with what we've witnessed over the past six quarters, which, as you'll recall, proved fairly robust.

Julia Qing

analyst
#14

Hello, and thank you for taking my question. I have just a couple of particular follow-ups regarding the guidance. On NovaSeq, I saw that you lowered the pull-through guidance to $1.1 million-$1.2 million. Since volume utilization is still fairly strong, are pricing factors involved in your revised guidance? Then, regarding Grail, you reduced it by $20 million. Given that NHS appears to be making good progress, could you clarify what factors are involved in that? Thank you.

Francis deSouza

executive
#15

Appreciate that, Julia. I'll start with what you asked about NovaSeq pull-through. To begin with, this isn't a matter of pressure on pricing. What you need to understand is that pull-through really results from several different elements, correct? It's the shipments made during the quarter split by how many instruments we anticipate being live at a given moment. Well, this quarter, both of those elements behaved in a manner that, you know, was temporary, and that caught us off guard. To start, even though, as Francis pointed out, correct, runs on our machines were robust thanks to inventory deleveraging, the count of shipments themselves — the numerator in that equation — came in a bit light. On top of that, since we had clients who purchased a big quantity of NovaSeqs in prior quarters, and owing to certain lab expansion hold-ups that were mentioned, a portion of those instruments never went live, correct? The denominator, given how pull-through gets calculated, ended up puffed up. Because of those two elements, we indeed observe a reduced pull-through figure this quarter. That said, looking ahead, with the robust growth in run counts that our instruments are experiencing among a wide array of our high throughput customers, and with the powerful market forces that are extremely intensive, sequencing, such as MRD, such as oncology testing, plus things like spatial and proteomics, we do anticipate that over the long term, this figure will keep expanding. I believe you also had another question, which was, oh, the Grail factor. A few points here, correct? As Francis said, Grail has already demonstrated that it's a test with very strong adoption. It shows the quickest revenue growth in year one following launch of any screening test available on the market, ever. Even though Grail's figures have come in somewhat under what was expected based on prior guidance, it remains a very robust test, and we're seeing genuinely strong uptake across numerous hospital systems nationwide. Our belief is that, you know, test ordering from those systems that have already made a commitment to Grail is going to rise, but at present, I think we stay quite optimistic regarding the test's quality and what it could achieve.

Tejas Savant

analyst
#16

Hi everyone, good evening. Let me start with a quick follow-up on pricing, though looking at it from a more forward-looking angle. Francis, you brought up that some customers are giving more thought to CapEx. A few of them are even going through restructurings, as we saw this quarter. I wanted to know how you see this weighing on growth in 2023, and maybe even more significantly, near term, does this alter at all the way you think about pricing for Chemistry X, backward compatibility options for Chemistry X, and similar things?

Francis deSouza

executive
#17

Sure, Tejas. When it comes to helping our customers as they navigate the macro challenges, clearly we stay close to them. The fact is, we sit at the core of their business and their revenue generation, and we're a very important supplier to them. While we can assist them in the sense that, given the strength and resilience of our supply chain, they feel more confident keeping less inventory on site, that clearly helps them with cash outlays. The fact is, they must keep serving the demand they're receiving, since that's what fuels their revenues, their growth, and their long-term success. We aren't seeing activity levels drop off from those customers, again, because we sit at the core of their revenue generation and their success; we remain close to them. We're also keeping close to the lab expansion plans and making sure we're on top of when they expect to receive equipment for the labs as those come online. On pricing, from where we stand, our thesis still holds that there's a huge opportunity to expand the genomics market by continuing to push the price down for high quality sequencing, highly accurate sequencing. That thesis still holds, certainly in the research markets, but also when it comes to opening up new clinical markets. We're seeing promising work, for instance, happening in areas such as cardiovascular disease and neurological disease. Those will require both very large experiments from a research perspective, but also perhaps different price points from a clinical perspective. We keep marching forward with the idea that part of our mission is to make genomics more accessible by driving costs down. When it comes to Chemistry X and the instruments, the way we think about it is, we're certainly capable from a technology perspective of making Chemistry X available on instruments already on the market. That's a lever we have. As we look at the market, we want to be sensitive to the fact that if customers have bought an instrument we launched fairly recently, they may not have gone through their depreciation cycle. We will give additional thought to putting Chemistry X onto those sorts of platforms. Yet when an instrument has already been sold for some time and has completed a depreciation cycle, we see a chance to assist that market in upgrading — letting them benefit not only from what Chemistry X introduces, but also from advances in all the remaining technology pieces, such as optics, or data paths, and genuinely bring out transformative new instruments. That is the way we look at it.

Puneet Souda

analyst
#18

Yes, hello, Francis. I appreciate you fielding this. To start, could you give us a broad-strokes picture of who these buyers actually are? I'm simply attempting to figure out whether they lean more toward COVID-related accounts, oncology accounts, or genome center accounts, and what their intentions are regarding lab expansion. That, I think, is the crux of the difficulty, since when we examine the life science tools businesses — the peer set you compete against — a number of them posted extremely robust growth; they ran into supply chain problems during Q1. As a matter of fact, those supply chain problems were even sharper. These labs have accepted shipment of many of these instruments. That explains why the peer companies posted such strong results. I'm just curious what sets this apart, with respect to Illumina instruments, or what makes these buyers distinctive. Then regarding Grail, I mean, you describe it as the most rapidly adopted test, yet at the same time you're bringing your guidance down. I'm just trying to figure out whether there's some special circumstance affecting particular customers there. Thanks.

Francis deSouza

executive
#19

Yes. We'll address both. Regarding the labs, and I believe your question concerns the labs pushing back their expansion plans — who exactly are they? You're essentially saying that a few of the other life sciences tools firms haven't encountered this. Let me characterize them for you a bit. To begin with, it's a small number of customers. Next, they are clearly genomics-focused buyers. They operate genomics labs. That might not show up among general life sciences tools, in the market overall, yet it definitely shows up in sequencing. These are typically customers that are expanding; they're the ones holding expansion plans, meaning they're successful customers. They're enjoying strong growth. In fact, they serve markets such as oncology, for instance, where they anticipate substantially greater demand ahead and are preparing to build, and are building, sizable labs. These are big customers, they are growing customers, and they are customers confronting substantially greater demand and wanting to grow their labs. Now, they're genomics labs, and they're mostly — they're essentially Illumina customers, so clearly, we're the ones that ride through that cycle alongside them. That's the reason you'd observe it with us, and that's the reason you'll observe it once those labs come online. That's the reason the benefit will land with Illumina. Those are the traits of the customers in question. Regarding Grail, it truly has been rather extraordinary to witness the tremendous growth they achieved in their inaugural year. Looking at their initial 12 months — and this June, they just completed their first 12 months — they represent the quickest revenue growth of any cancer screening test ever recorded. That's rather extraordinary, isn't it? They're doing an outstanding job too when it comes to getting health systems and employers to sign on. Here's another illustration of the sheer speed at which this is progressing. During the most recent quarter, they got the 140,000-person trial for the NHS completely enrolled. Normally, a study of that size would need years before enrollment finished, yet the NHS, partnering with Grail, managed it in 10 and a half months. That tells you something about the acceptance out there, the appetite in the market, the demand in the market for a breakthrough test of this kind, correct? The fact that 50 cancers can be detected across all stages, and folks are beginning to grasp the results of their bringing it to market. So what we're focused on right now, even with that toward, you know, growth phase, is the remainder of the year, and we're focused on the ramp up occurring at a number of the health systems that have signed up along with a number of the employers. You know, some of their estimates for the rest of the year have been trimmed back by the Grail team. That doesn't change the fact, again, that this is the fastest-growing cancer screening test ever witnessed in history.

Kyle Mikson

analyst
#20

Hi there, I appreciate you fielding these. I have a handful regarding the outlook. I'm wondering what makes up the 1.5% year-over-year increase in instrument revenue for 2022. Joydeep, could you perhaps discuss what you anticipate for placements, orders, and pricing — is pricing fixed at this stage or still flexible? Given what was said about backlog, it came in quite robust as the year began and more recently, so how is that shaping up lately and looking ahead. On a similar note, regarding the drop in mid-throughput shipments year-over-year during 2Q, I understand the points about China and other elements, yet could part of that stem from the platform evaluation process as new vendors come into the market or at minimum create some buzz? Since clearly these big clinical labs are already trying out these offerings, so it seemed worth bringing up. Thank you.

Francis deSouza

executive
#21

Yes. Appreciate it, Kyle. I'll begin with the 2Q aspect concerning mid-throughput, okay? Like I said earlier, orders in that mid-throughput category were genuinely quite robust, correct? We observed ongoing demand with solid order volumes for NextSeq 1K, 2K — that's our newest offering in that space — rising significantly. Although we hit a short-term supply chain problem on our side that stopped us from shipping those orders during 2Q, they've already gone out since then in the current quarter. We're quite hopeful, and we're seeing incredibly robust need and enthusiasm for our mid-throughput offering, from both research and clinical clientele. Regarding the whole year, there are a few points, okay? Begin with NovaSeq, okay? Our initial six months were solid. Orders during that period rose 30% compared to the prior year; and as we noted, there was 23% expansion in Q2. This concerns a platform that is now 6 years past its introduction, correct? We're seeing hugely strong, unmatched demand even following an exceptionally robust 2021. That's thrilling for us. Also keep in mind that the majority of these instruments are already placed now. We anticipate that consumables pull-through from these machines is coming and will keep speeding up in the coming quarters and years. We're quite confident in our lineup, across both the high-throughput and mid-throughput categories.

Patrick Donnelly

analyst
#22

Hi everyone, appreciate you taking my questions. Francis, this one might be for you, regarding the operational spending you're currently undertaking. You clearly mentioned the drop in operating margin for the second half. Could you discuss how you're managing the trade-off between certain growth investments while also staying careful about shielding the margin and safeguarding the bottom line? Naturally, Chemistry X and Infinity are on the way. I'd imagine you'd want to put money into the launches for those. Perhaps you could speak once more to that balancing act of funding growth, yet simultaneously recognizing that as things decelerate, there's a need to defend the bottom line somewhat, and tell us where you're scaling back versus where you're pressing ahead. Thanks.

Francis deSouza

executive
#23

Yes, certainly, Patrick. Clearly, given the updated projection for revenue this year, we're reviewing what we spend, and just like you mentioned, we're striking that equilibrium. On one side, we're seeking out places to keep expenses in check. That involves, you know, reducing things that are optional, such as travel along with other non-essential outlays. We're additionally making choices about which recruiting to focus on first. Certain positions we'll delay filling, since we feel they aren't critical at this moment. The team is definitely engaged in that review. That said, we're simultaneously safeguarding our innovation pipeline, plus key new hires elsewhere in the organization as the business grows. You know, our product ambitions are quite bold, as you're aware. We're going to keep shielding that pipeline since it's what fuels, you know, our customers' achievements and our success over the long haul, and that's what generates enduring shareholder value for the company. That's the equilibrium we're striking. We're safeguarding the innovation pipelines, we're safeguarding the efforts that, you know, produce that long-term shareholder growth, encompassing items like, you know, expanding capacity, IVD capabilities, commercial growth in selected markets, and so we keep up that equilibrium.

Joydeep Goswami

executive
#24

Right, and I'd mention too that we're still seeing gains in productivity when it comes to gross margin, correct? Naturally, that holds even with the lower volume we've experienced this year, and a few of those gains are helping lift both gross and operating margin as well.

Vijay Kumar

analyst
#25

Hi, everyone. I appreciate you taking my question. Francis, I might have a two-part one for you. For the back half, your guidance points to 1% growth. You just delivered 3% in 2Q. Does this outlook assume things get worse than they were in 2Q? Since, as I understood you, a number of these are temporary factors. Looking at the inventory you're holding, I doubt your customers buy 12 months ahead. So shouldn't a few of those factors swing back? How cautious is this guidance for the back half? Then regarding Chemistry X, I believe we've heard about a 30% price reduction, 20%-30%, roughly around there. Does that carry any effect on revenue growth for fiscal 2023? Thank you.

Francis deSouza

executive
#26

Yes. Thanks, Vijay. I'll begin with the first portion of your question, which is, well, Q3 guidance or what's behind that figure. I'll go through a few of the elements that are, well, behind that figure. If you strip out the impacts I'm referring to, growth comes in higher, and I'll return to that point too. A few of the elements behind it are, well, the headwinds I mentioned. One headwind involves COVID surveillance demand easing off. That's continuing through Q3 as well. There's clearly a foreign exchange headwind plus the difficult comparison with the UK Biobank that wraps up in Q3. That's yet another element continuing through Q3. We also anticipate GDP growth in China staying slower, and that will affect us; after that, the two elements I mentioned, roughly inventory management plus the lab expansion. Correct. Those are a few of the elements we took into account when providing the guide for Q3. Clearly, if you strip out those elements, then you're facing a considerably higher growth rate in Q3.

Jack Meehan

analyst
#27

Thanks. Good afternoon. Francis, regarding Grail, I've got a question with two parts for you. First, with this drawn-out regulatory ambiguity, is there any threshold at which you might decide to step away? How confident are you that this will get completed? And then secondly, clearly the current climate isn't the friendliest for capital markets activity. If you ended up having to spin Grail out, how would you finance the continuing operations? Looking at your balance sheet following the BGI payment and the penalty you've set aside for the European Commission, you've got about $550 million in unrestricted cash. Just address, if you reached that point, how you'd fund a spin if, you know, if it comes to that?

Francis deSouza

executive
#28

You know, I'll begin by saying that we're going to stay focused on and keep thinking about what generates the greatest long-term shareholder value. You know, when we started down this path, as you mentioned, we definitely believed that bringing Grail and Illumina together produces the greatest long-term shareholder value. Let me give an illustration, right? Even mostly on their own, the Grail team managed the quickest 12-month ramp of any cancer screening test in history, as we've stated; now picture what that might have looked like, you know, with Illumina's strength supporting it. Looking ahead, you know, what might we accomplish if we could bring that test into markets such as Europe and Asia and Africa beyond what Grail alone could plan. that's kind of what shaped our thinking. That said, you know, we're going to keep evaluating as we move through this process, what the proper next steps are. You know, there clearly are certain nodes on the decision tree that would cause us to either spin out Grail because the regulatory process doesn't favor us or consider other, you know, kinds of exit. We're going to keep evaluating that as we proceed through the regulatory process. As for, you know, your question about, you know, financing the operations, that's definitely going to be something we weigh as we consider the options and how we'd need to spin Grail out, right? The aim is that what you'd want to do is ensure that you know, safeguarded the asset value so Grail can keep executing on its mission. That means ensuring it's capitalized so it can remain successful, and also that it has access to future capital it will require for its own expansion plans. That's going to involve a mix of Illumina, but other shareholders as well, potentially, and other parties who put in capital, both perhaps at the moment of divestiture, but then over time too. You know, those are a few of the considerations as we think about what a divestment would involve. You see, what approach would we take to give it a good shot at working, and what route exists for it to keep working well? Clearly, we aren't deciding those things right now, but those are a few of the factors that would factor in.

Operator

operator
#29

Everyone, that brings us to the end of today's call. Thank you for joining us. You're welcome to leave the line now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.